Localized Prostate Cancer VL

Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas

Details
Daniel Barocas joins Alicia Morgans in a conversation on the prospective population-based Comparative Effectiveness Analysis of Surgery And Radiation (CEASAR) study which assess rates and predictors of patient-reported treatment regret among men deciding on treatment for localized prostate cancer. The CEASAR Study began accruing patients in 2010 and has a population-based cohort of almost 3000 men...

Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz

Details
Laurence Klotz joins Phillip Koo at the 13th International Uro-Oncology Congress in São Paulo, Brazil in a discussion on Active Surveillance (AS), High-intensity focused ultrasound (HIFU), and focal therapy in Latin America and developing countries. There are challenges with active surveillance in developing countries that might not have formal prostate cancer screening programs, a lack of resourc...

Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb

Details
Alicia Morgans is joined by Stacy Loeb to discuss her presentation at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on the risks and the benefits of active surveillance in the intermediate-risk population. Over the last several years, there has been an increase in the utilization of active surveillance in the United States for patients with intermediate r...

Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp

Details
The Scientific Director at the Society of Oncology and Hematology from del Cesar, Columbia, Ray Manneh Kopp joins Phillip Koo bringing a global perspective to a discussion on the novel approaches in the management of high-risk prostate cancer. They discuss the diagnosis criteria currently being used, the novelties in the diagnosis, and adjuvant alternatives in this disease. Biographies: Ray Manneh...

The Benefit of ADT Treatment Intensification with Radiotherapy for Men with Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss MARCAP, a meta-analysis of randomized trials in cancer of the prostate. This individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer in aggregate and in clinically releva...

Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain & Christopher Dee

Details
Paul Nguyen discusses a groundbreaking paper on health equity in prostate cancer with its authors, Bhav Jain and Christopher Dee. The paper focuses on racial disparities in treatment delays among younger men with prostate cancer. Utilizing the National Cancer Database, the study reveals that young Black men experience treatment delays more frequently than their older Black or White counterparts. T...

Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn't. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be pre...

Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks

Details
Alicia Morgans and Michael Brooks discuss a recent manuscript entitled, “Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-years After Radical Prostatectomy”. Dr. Brooks goes into depth on how adverse pathology correlates with long-term prostate cancer outcomes. They also discuss active surveillance for low-risk patients and how to stratify th...

Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein

Details
Alicia Morgans and Eric Klein discuss two papers that involve a unique cohort of patients with early-stage prostate cancer. Dr. Klein details the use of the Oncotype GPS score to stratify patients and determine who is safe for active surveillance. They also discuss how to use MRI histology, adverse pathology, and genomic profiling systems together. They discuss advising clinicians on how to start...

AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt

Details
In this conversation with Alicia Morgans, Daniel Spratt discusses artificial intelligence (AI)-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition o...